SQI Diagnostics Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Andrew Morris

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	2.8yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	4.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	11.9yrs

Jüngste Management Updates

Recent updates

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Dec 22

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Nov 17

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Andrew Morris im Vergleich zu den Einnahmen von SQI Diagnostics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2023	n/a	n/a	-CA$19m
Dec 31 2022	n/a	n/a	-CA$18m
Sep 30 2022	CA$543k	CA$400k	-CA$19m
Jun 30 2022	n/a	n/a	-CA$13m
Mar 31 2022	n/a	n/a	-CA$9m
Dec 31 2021	n/a	n/a	-CA$10m
Sep 30 2021	CA$265k	CA$265k	-CA$11m
Jun 30 2021	n/a	n/a	-CA$11m
Mar 31 2021	n/a	n/a	-CA$12m
Dec 31 2020	n/a	n/a	-CA$10m
Sep 30 2020	CA$265k	CA$265k	-CA$9m
Jun 30 2020	n/a	n/a	-CA$9m
Mar 31 2020	n/a	n/a	-CA$9m
Dec 31 2019	n/a	n/a	-CA$8m
Sep 30 2019	CA$348k	CA$300k	-CA$8m
Jun 30 2019	n/a	n/a	-CA$7m
Mar 31 2019	n/a	n/a	-CA$7m
Dec 31 2018	n/a	n/a	-CA$7m
Sep 30 2018	CA$330k	CA$300k	-CA$7m
Jun 30 2018	n/a	n/a	-CA$7m
Mar 31 2018	n/a	n/a	-CA$7m
Dec 31 2017	n/a	n/a	-CA$6m
Sep 30 2017	CA$300k	CA$300k	-CA$6m

Vergütung im Vergleich zum Markt: Unzureichende Daten, um festzustellen, ob die Gesamtvergütung von Andrew im Vergleich zu Unternehmen ähnlicher Größe auf dem Markt Canadian angemessen ist.

Entschädigung vs. Einkommen: AndrewDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Andrew Morris (58 yo)

2.8yrs

Amtszeit

CA$543,040

Vergütung

Mr. Andrew Morris serves as the Chief Executive Officer, Chief Financial Officer, President & Director of Rose Diagnostics Inc. Mr. Morris is Chief Executive Officer of SQI Diagnostics Inc. from September...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Andrew Morris	Advisor to the Board & CEO	2.8yrs	CA$543.04k	keine Daten
Morlan Reddock	CFO & VP of Administration	4.3yrs	CA$200.00k	keine Daten
Eric Brouwer	Chief Scientific Officer & Advisor to the Board	6.8yrs	CA$350.00k	keine Daten
Peter Lea	Founder	25.5yrs	keine Daten	keine Daten
Tim McGough	Chief Commercial Officer	1.8yrs	keine Daten	keine Daten

4.3yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrenes Management: SQDDas Führungsteam des Unternehmens gilt als erfahren (3.5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Gerald Connor	Independent Director	9.3yrs	keine Daten	24.46% CA$ 1.5m
Yehuda Shoenfeld	Chairman of Scientific Advisory Board	14.5yrs	keine Daten	keine Daten
Claude Ricks	Independent Director	17.2yrs	CA$4.00k	keine Daten
Eric Zwisler	Independent Director	6.1yrs	keine Daten	keine Daten

11.9yrs

Durchschnittliche Betriebszugehörigkeit

71yo

Durchschnittliches Alter

Erfahrener Vorstand: SQD.HDie Vorstandsmitglieder sind sehr erfahren ( 11.9 ).

SQI Diagnostics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Insufficient new directors

SQI Diagnostics Inc., Annual General Meeting, Apr 05, 2023

Independent Director recently sold CA$56k worth of stock

Recent updates

SQI Diagnostics Inc. Ordinary Shares to Be Deleted from OTC Equity

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)

Insufficient new directors

First quarter 2023 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 1Q 2022)

SQI Diagnostics Inc., Annual General Meeting, Apr 05, 2023

Full year 2022 earnings released: CA$0.048 loss per share (vs CA$0.031 loss in FY 2021)

SQI Installs Two Rali-Dx Systems in Toronto Hospitals to Fight the Growing Respiratory Health Crisis in Emergency Departments

SQI Diagnostics Inc. announced that it expects to receive CAD 1 million in funding

SQI Diagnostics Inc. announced that it expects to receive CAD 2 million in funding from Federal Economic Development Agency for Southern Ontario

SQI Diagnostics Announces Health Canada Approval of RALI-Dx Severity Triage Test

Third quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.002 loss in 3Q 2021)

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics (CVE:SQD) Has Debt But No Earnings; Should You Worry?

New York State Approves SQI Diagnostics' Exact Covid-19 Antibody Assay

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics Systems Inc. signed a definitive agreement to acquire all of the assets underlying Precision Biomonitoring Inc businesses from Precision Biomonitoring Inc. for CAD 6.825 million

SQI Diagnostics Inc. announced that it expects to receive CAD 6 million in funding

Third quarter 2021 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2020)

Is SQI Diagnostics (CVE:SQD) Weighed On By Its Debt Load?

FDA Stops Emergency Use Authorization Review of SQI Diagnostics Inc. RALI-Dx IL-6 Severity Triage Test for Covid-19 Patients

CEO & Director Robert Chioini has left the company

Second quarter 2021 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 2Q 2020)

Health Check: How Prudently Does SQI Diagnostics (CVE:SQD) Use Debt?

Independent Director recently sold CA$56k worth of stock

Are Insiders Buying SQI Diagnostics Inc. (CVE:SQD) Stock?

First quarter 2021 earnings released: CA$0.012 loss per share (vs CA$0.009 loss in 1Q 2020)

Director exercised options to buy CA$705k worth of stock.

Director recently bought CA$660k worth of stock

New 90-day high: CA$0.40

SQI Diagnostics Inc., Annual General Meeting, Mar 31, 2021

Full year 2020 earnings released: CA$0.032 loss per share (vs CA$0.045 loss in FY 2019)

Is SQI Diagnostics Inc. (CVE:SQD) Popular Amongst Insiders?

SQI Diagnostics Announces Patient Enrollment Begins for its COVID-19 HOME Antibody Test Clinical Study

New 90-day high: CA$0.28

Independent Director exercised options to buy CA$1.7m worth of stock.

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Sqi Diagnostics Inc. Updates Clinical Progress on Novel Covid-19 Tests Under Development for U.S. Fda Regulatory Submission

Third quarter earnings released

SQI Diagnostics Inc. Announces Executive Changes

New 90-day high - CA$0.21

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter